修复辅助损伤检测(RADD)作为卵巢癌免疫治疗反应的预测生物标志物
研究对VITAL试验中82例卵巢癌肿瘤样本行修复辅助损伤检测(RADD)评估DNA损伤,分析其与生存、CD39表达及基因表达特征的关系。RADD评分可预测同源重组状态(p<0.001),与CD39相关(r=0.473;p<0.001),高RADD评分者接受Vigil维持治疗的无复发生存期优于安慰剂(25.1 vs 11.7个月,p=0.005)。
要点
- RADD评分可预测卵巢癌同源重组状态(p<0.001)。
- RADD与CD39表达显著相关(r=0.473;p<0.001),HRP肿瘤中r=0.57(p=0.002)。
- 高RADD评分者接受Vigil的无复发生存期优于安慰剂(25.1 vs 11.7个月,p=0.005)。
核心结论
- RADD可揭示DNA修复能力,无需突变特征或表达谱分析。
- 高DNA损伤水平者接受Vigil维持治疗生存改善,且与免疫逃逸蛋白相关。
- 基因组DNA中DNA损伤的持续存在为免疫治疗患者分层提供了新生物标志物。
研究设计与样本
- 对VITAL试验(NCT02346747)中82例福尔马林固定石蜡包埋肿瘤行修复辅助损伤检测(RADD)。
- VITAL试验比较Vigil(gemogenovatucel-T)维持治疗与安慰剂用于IIIB-IV期新诊断且临床完全缓解的卵巢癌。
主要发现
- 82例卵巢样本RADD评分呈梯度分布。
- RADD评分可预测同源重组状态(p<0.001)。
- RADD与CD39显著Pearson相关(r=0.473;p<0.001),HRP肿瘤中r=0.57(p=0.002)。
- 安慰剂组高RADD评分与更差无复发生存期相关(高 vs 低:7.9 vs 14.7个月;p=0.066)。
- 高RADD评分者Vigil较安慰剂显著改善39.4个月内的无复发生存期(25.1 vs 11.7个月,p=0.005),总生存期有改善但未达显著(38.8 vs 31.8个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Genomic instability has been proposed as a predictive biomarker for immunotherapy in ovarian cancer. We tested a method for measuring DNA damage, a direct measure of genomic instability, in ovarian tumors and its ability to predict immunotherapy response to Vigil (gemogenovatucel-T). METHODS: Eighty-two formalin-fixed paraffin-embedded tumors from the VITAL trial (NCT02346747) underwent DNA damage assessment using Repair Assisted Damage Detection (RADD). VITAL tested maintenance Vigil therapy vs. placebo for stage IIIB-IV newly diagnosed ovarian cancer in clinical complete response. DNA lesion levels determined by RADD were scored and assessed against patient survival outcomes, expression of CD39, and gene expression signatures. RESULTS: A graduated distribution of RADD scores occurred across all 82 ovarian samples. RADD scores were able to predict HR status (p < 0.001). RADD demonstrated a significant Pearson's correlation with suggested Vigil biomarker CD39 (r = 0.473; p < 0.001), specifically within HRP tumors (r = 0.57; p = 0.002). High RADD scores correlated with worse recurrent free survival (RFS) in the placebo arm of the trial (7.9 vs. 14.7 months, high vs. low; p = 0.066). High RADD scores were also predictive of significant RFS over 39.4 months with Vigil compared to placebo (25.1 vs. 11.7 months, p = 0.005) and improved, but not significantly, OS with 38.8 vs. 31.8 months. CONCLUSIONS: RADD revealed DNA repair proficiency without mutation signatures or expression profiling. High DNA damage levels show improved survival for Vigil maintenance therapies and are correlated with immune evasion proteins. The persistence of DNA lesions in the genomic DNA offers a new biomarker for immunotherapy patient stratification.
引用
- Sonavane M, Hedlich-Dwyer J, Dal Zotto VL, et al. Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer. Gynecol Oncol. 2024. PMID: 39546931. doi:10.1016/j.ygyno.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。